Bayer wins OK for hemophilia A treatment; Agenus sells off a slice of future royalties for $15M

→ Japanese officials have approved Bayer’s hemophilia A drug Jivi (BAY94-9027), a Factor VIII treatment.

Xoma is tapping into their line of credit at Silicon Valley Bank to help pay a $15 million tab to buy into Agenus’ royalty stream due for its licensing rights to immuno-oncology drugs being developed by Merck and Incyte. “This is an important deal reflecting our new royalty-aggregator strategy to acquire milestone and royalty payments associated with therapeutic candidates partnered by others,” said Xoma CEO Jim Neal.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 35,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Biotech Investment Analyst
SV Health Investors Boston, MA
Research Scientist - Disease Biology
Recursion Pharmaceuticals Salt Lake City, UT
Senior Scientist - Predictive Pharmacology
Recursion Pharmaceuticals Salt Lake City, UT
Director, Translational Sciences
Cadent Therapeutics Cambridge, MA
Director of Marketing
twoXAR Mountain View, CA

Visit Endpoints Careers ->